TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean Percent Change in PASI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cleansing score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alanine Aminotransferase (ALAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in adolescent mental health symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in parent mental health symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in parent-child conflict
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in parent-child relationship quality
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Quality of capsule endoscopic images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stomach and small bowel transit times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capsule completion rates to the end of the small bowel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Determination of clinical symptomatics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Determination of psychological symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PROMIS Pain Interference
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: In-Hospital Quality of Care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: glycosolated hemoglobin (HbA1c) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in CSFQ-14 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence and incidence of cytomegalovirus resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Monocular Uncorrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maintenance of Best Spectacle Corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin detemir pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Initiation of sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Healing of local wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic reactions (fever, nausea, vomiting, skin itching)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse outcomes in first 30 days after discharge from NICU
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Achieving SALT Score of 50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety assessed by recording of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics assessment of ASG-5ME blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incidence of progression to ESRD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: cardiovascular event
Endpoint domain: Mortality/survival
Primary endpoint: Mean increase in Pro-collagen type 1 N-terminal propeptide (P1NP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24 hour urinary phosphorous excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cell Mediated Immune (CMI) Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum (Peak) Plasma Concentration (Cmax) of Brexpiprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve Calculated to the Last Observable Concentration at Time t (AUCt) of Brexpiprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events related to laser assisted IVC filter removal
Endpoint domain: Adverse events/effects
Primary endpoint: Jebsen Hand Function Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the ratio of central venous-to-arterial CO2 tension or content to arterial-to-central venous O2 content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with active inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Last Measurable Concentration [AUC(0-T)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WELCH questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum Tolerated Dose
Endpoint domain: Adverse events/effects
Endpoint subdomain: Dose Limiting Toxicity
Primary endpoint: Proportion of patients with therapeutic cure of scabies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-hr postprandial plasma glucose (PPPG) excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Carcinologic efficacy at the site of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Compliance rates with care guidelines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Metabolic parameters in postprandial state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inflammatory markers in postprandial state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pharmacokinetic of Niacin and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Emotional Exhaustion Burnout Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Depersonalization Burnout Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Personal Accomplishment Burnout Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time for relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in proliferation by Ki-67 immunohistochemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability rates related to deep brain stimulation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical Global Impression of Tolerability (CGIT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetic Parameter: Area Under the Curve (AUC)(0-24hr) of E2007
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tampa Scale for Kinesiophobia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Western Ontario and McMaster Universities Arthritis Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arthritis Self Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Tolerated Dose of AZD5312
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of AZD5312
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 Dose of AZD5312
Endpoint domain: Adverse events/effects
Primary endpoint: Transcutaneous tissue oxygen tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum insulin aspart concentration-time curve from 0 to t hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Acute hypercapnic respiratory failure resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: citizenship
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: COVID-19 Stress Scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: D-dimer trends
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduced inhaled corticosteroid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maturation of Collagen Matrix
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with HBV DNA below 12 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Delineation of dysplastic tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in policy and practice
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percent of enrolled Phase I subjects who complete a provider visit by 3 months post enrollment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increase in fetal hemoglobin (HbF) as measured by hemoglobin electrophoresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Degree of correction measured by talonavicular coverage angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative gene expression in plasmacytoid dendritic cells (pDCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recovery after breast augmentation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline Arm Movement Ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of active lesions in MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Specificity and sensitivity of the ELISAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of OAB symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of the number of epileptic seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stability of the cognitive assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Duration of Disease-Free Survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: hemidiaphragmatic paralysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area Under the Curve at Steady State (AUCss) of Balovaptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration of Balovaptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration of M2 Metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of households using the toilet
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: correlation between S-MRCP and ePFT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration from concussion to physiological rehabilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Albumin creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Magnitude and complexity of ventricular and atrial arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infection rates after hernia repair
Endpoint domain: Adverse events/effects
Primary endpoint: End-tidal carbon dioxide (ETCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: StO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oocyte fertilization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate pace and quality of early embryonic development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Daily glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cognition tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: patients compliance in taking split-dose preparation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change From Baseline in Log Transformed Binge Days Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QRS-interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of women who quit smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: trait-anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Immune tolerance and donor cell engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of fetal intrap
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of fetal intrap
Endpoint domain: Resource use
Primary endpoint: Safety based on NCI-CTCAE v4.03
Endpoint domain: Adverse events/effects
Primary endpoint: Toronto Clinical Neuropathy Scoring System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post-operative change in ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Erectile dysfunction and/or incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Changes in Visual Analog scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of virologically confirmed (PCR positive) symptomatic cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Behavioral Performance (Accuracy) on Cognitive Tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Behavioral Performance (Reaction Time) on Cognitive Tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Tooth Vitality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of the restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AChE levels in fetal blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fraction of time without CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chest compression frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peel Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or Poor Neurologic Outcome
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients reaching ≥70% of the cumulative target for protein delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of thermal pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Explants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in psychosomatic stress symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Day of the estimated beginning of the fertile phase of the menstrual cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Day of the estimated peak of the fertile phase of the menstrual cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Day of the estimated end of the fertile phase of the menstrual cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Days of smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of change in medical management with beta-blockers, diuretics and sacubitril/Valsartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Immune response evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Patients Achieving Complete or Near Complete Drainage of Loculated Pleural Effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Hemorrhagic Complications Associated With Catheter Drainage
Endpoint domain: Adverse events/effects
Primary endpoint: safety of m-IPV2 HD and licensed trivalent IPV
Endpoint domain: Adverse events/effects
Primary endpoint: reactogenicity of m-IPV2 HD and licensed trivalent IPV
Endpoint domain: Adverse events/effects
Primary endpoint: Within-subject standard deviation in duration of action of glargine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Within-subject coefficient of variation in time-action profile of glargine for AUC-GIR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Within-subject coefficient of variation in time-action profile of glargine for GIRmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paravalvular leak closure success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in preschooler BMI z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in caregiver BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: baseline-adjusted mean QTcF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Upper limb Motor Status Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Upper Extremity Motor Performance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary mortality
Endpoint domain: Mortality/survival
Primary endpoint: KDIGO AKI grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: aversive and appetitive learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scintigraphic visualisation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responsiveness of the LPDS instrument
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ADE Geriatric risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from Chronic GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GH-receptor signaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Frequency of glucose monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of skin tumors per patient requiring surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Best modality of ICG injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stroke/TIA/systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: levels of CD247-zeta chain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximal MAP fluctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal change of SVV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LLSS self- and clinical assessments score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parapapillary choroidal microvasculature void (MvV) area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous thrombosis and/or pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Average Coefficient of Friction of Worn Lenses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MRI Tractography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of ventilator associated pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Eosinophilic Degranulating Protein Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cumulative morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postpartum maternal smoking abstinence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Area under the GIR curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Downes and Raphaelly respiratory distress scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical Global Improvement and Severity scales (CGI-I and CGI-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overt Aggression Scale-Modified (OAS M)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing